Prostate Anat+Path
-
MRCS B Prostate Gland
Stem: A 68-year-old man presents to his GP with a 6-month history of increasing urinary frequency, nocturia, and a weak urinary stream with hesitancy. He denies any haematuria or weight loss. On examination, his abdomen is soft and non-tender, with no palpable bladder.What are the superior and inferior relations of the prostate gland?
Superior – neck of the bladder
Inferior – external urethral sphincterDescribe the zonal anatomy of the prostate. Which zone is most commonly affected by carcinoma, and which by benign hyperplasia?
Peripheral zone – largest zone, most common site of prostate carcinoma, palpable on DRE
Transition zone – surrounds the urethra, most common site of benign prostatic hyperplasia
Central zone – surrounds the ejaculatory ductsWhat is the arterial supply to the prostate?
Inferior vesical artery, from the anterior division of the internal iliac artery.
What is the venous drainage of the prostate and how is it implicated in prostatic malignancy?
Prostatic venous plexus
Has a connection with the valveless vertebral veins, which may be a passage of spread of malignancy.Prostate symptoms can be classified as storage or voiding symptoms, give two examples of each.
StorageFrequency
Nocturia
Urgency
IncontinenceVoiding
Terminal dribbling
Slow stream
Slow to start voidingWhat is an important part of the examination of a male patient with storage or voiding symptoms? How may we distinguish between benign or malignant pathology?
Digital rectal examination.
May feel a smooth enlargement suggestive of benign disease, or a craggy, hard mass, which would suggest malignant disease.What tumour marker is used to help diagnose and monitor prostate cancer, and what are its limitations?
Prostate-specific antigen (PSA)
Not specific to malignancy – can also be raised in BPH, prostatitis, and after instrumentation (e.g. catheterisation, DRE)
Lacks sensitivity and specificity, so used alongside DRE and biopsy rather than as a standalone diagnostic testGive two options for the pharmacological management of benign prostatic hyperplasia.
5-alpha reductase inhibitors – e.g. Finasteride.
Anticholinergic agents – e.g. Tolterodine
Alpha blockers can also be used.Give two risk factors for prostate cancer.
Ethnicity – more common in people of black ethnicity.
Age – people aged over 50 are much more likely to have prostate malignancy.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Register Login